- New York AG Letitia James reached agreements with Eli Lilly and Company and Sanofi-Aventis U.S. LLC to resolve an investigation into insulin pricing practices which found that the list prices set by insulin manufacturers have increased dramatically over the past two decades, and make the product unaffordable to many insulin users.
- Under the terms of the agreements, Lilly and Sanofi will cap the price of insulin at $35 per month for uninsured New Yorkers for the next five years; continue working with national relief agencies to offer free insulin through eligible non-profit clinics in high-need areas; and provide free insulin to the highest-need consumers who are below the poverty line.
- The companies also agreed to clearly disclose insulin affordability offerings to consumers and provide information regarding how to apply for these offerings, among other things.